Aldeyra Therapeutics, Inc. (ALDX) Analysts See $-0.32 EPS

March 28, 2018 - By Hazel Jackson

 Aldeyra Therapeutics, Inc. (ALDX) Analysts See $ 0.32 EPS
Investors sentiment decreased to 1.62 in 2017 Q4. Its down 1.51, from 3.13 in 2017Q3. It turned negative, as 5 investors sold Aldeyra Therapeutics, Inc. shares while 8 reduced holdings. 9 funds opened positions while 12 raised stakes. 9.98 million shares or 45.35% less from 18.26 million shares in 2017Q3 were reported.
Woodstock Corp owns 58,243 shares. Adage Capital Ptnrs Grp Inc Ltd Liability Com invested in 0.01% or 693,000 shares. 1,400 were accumulated by Macquarie Gp Ltd. Ardsley Advisory Prtnrs reported 0.04% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Royal State Bank Of Canada holds 0% or 64 shares. Deutsche Savings Bank Ag holds 1,700 shares. Comml Bank Of America Corporation De holds 3,500 shares. Peddock Advisors Limited Liability Company has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). State Street stated it has 22,669 shares. 683 Cap Mgmt Limited Company stated it has 1.12 million shares. Bancshares Of Ny Mellon stated it has 18,378 shares or 0% of all its holdings. Sphera Funds Mngmt accumulated 1.04 million shares. Blackrock stated it has 37,694 shares or 0% of all its holdings. Hightower Advisors Lc invested in 16,250 shares. Knoll Cap Management Ltd Partnership has 0.74% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX).

Analysts expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report $-0.32 EPS on March, 29.They anticipate $0.04 EPS change or 11.11 % from last quarter’s $-0.36 EPS. After having $-0.32 EPS previously, Aldeyra Therapeutics, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 5.99% or $0.5 during the last trading session, reaching $7.85. About 98,328 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has risen 55.45% since March 28, 2017 and is uptrending. It has outperformed by 43.90% the S&P500.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Ratings Coverage

Among 6 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc has $27 highest and $900 lowest target. $18.80’s average target is 139.49% above currents $7.85 stock price. Aldeyra Therapeutics Inc had 13 analyst reports since August 13, 2015 according to SRatingsIntel. H.C. Wainwright initiated Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) rating on Monday, September 26. H.C. Wainwright has “Buy” rating and $18 target. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has “Buy” rating given on Thursday, June 15 by H.C. Wainwright. H.C. Wainwright maintained the shares of ALDX in report on Wednesday, August 9 with “Buy” rating. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, October 24. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, June 14. The company was maintained on Thursday, November 9 by Cantor Fitzgerald. The rating was initiated by Cowen & Co with “Outperform” on Tuesday, September 8. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) earned “Buy” rating by Canaccord Genuity on Wednesday, September 13. As per Thursday, September 14, the company rating was maintained by Cowen & Co. Stifel Nicolaus initiated the shares of ALDX in report on Friday, July 1 with “Buy” rating.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $150.07 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.